WHO call for public consultation on preferred product characteristics (PPCs) on tests for risk of P. vivax relapse
This groundbreaking initiative aims to advance malaria diagnosis and treatment by identifying and assessing the risk of P. vivax relapse in patients. With a focus on improving patient outcomes and combatting malaria's persistent nature, the WHO's guidelines offer valuable insights for healthcare professionals and researchers worldwide.
The PPCs is available for review and comments until 31 August 2023. More information on the WHO website.